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Abstract 30 
Factors influencing uptake and timing of risk reducing salpingo-oophorectomy 31 
in women at risk of familial ovarian cancer: a competing risk time to event 32 
analysis. 33 
Objective 34 
To evaluate factors affecting uptake of risk-reducing salpingo-oophorectomy(RRSO) 35 
over time in women at high-risk of familial ovarian cancer.  36 
Design  37 
Prospective observational cohort  38 
Setting  39 
Tertiary high-risk familial gynaecological cancer clinic  40 
Population/Sample 41 
New clinic attendees between March-2004 and November-2009, fulfilling high-risk 42 
criteria for the UK Familial Ovarian Cancer Screening Study. 43 
Methods 44 
Risk management options discussed included RRSO and ovarian surveillance. 45 
Outcomes data were analysed from a bespoke database. The competing risk method 46 
was used to model the cumulative incidence function(CIF) of RRSO over time, and 47 
Sub-Hazard ratio(SHR) to assess the strength of association of variables of interest 48 
with RRSO. Gray’s test was used to evaluate the difference in CIF between two 49 
groups and multivariable competing risk regression analysis to model the cumulative 50 
probabilities of co-variates on the CIF. 51 
Results 52 
Of 1133 eligible women 265(21.4%) opted for RRSO and 868(69.9%) for screening. 53 
Women undergoing RRSO were older (49years,IQR-12.2) than those preferring 54 
 3
screening (43.4years,IQR-11.9)(p<0.0005). The cumulative probability(CIF) for 55 
RRSO at 5years was 0.55(CI0.45,0.64) for BRCA1/2 carriers and 0.22(CI0.19,0.26) 56 
for women of unknown mutation status(p<0.0001); 0.42(95%CI0.36,0.47) for 57 
postmenopausal women(p<0.0001); 0.29(95%CI0.25,0.33) for parity ≥1(p=0.009) 58 
and 0.47(95%CI 0.39,0.55) for a personal history of breast cancer(p<0.0001). 59 
Variables of significance from the regression analysis were: a BRCA1/2 60 
mutation(SHR 2.31(CI 1.7, 3.14)), postmenopausal status(SHR2.16(CI 1.62,2.87)) 61 
and a personal history of breast cancer(SHR1.5(CI 1.09,2.06)).  62 
Conclusions  63 
Decision making is a complex process and women opt for surgery many years after 64 
initial risk assessment. BRCA carriers, postmenopausal women and women who had 65 
breast cancer are significantly more likely to opt for preventative surgery. 66 
 67 
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Introduction 73 
Mutations in the BRCA1/2 genes contribute to most of the known ovarian cancer risk 74 
in women at increased risk for familial ovarian cancer, with a number of moderate to 75 
low penetrance variants accounting for the residual familial risk. Women carrying a 76 
BRCA1 or BRCA2 mutation have up to a 49-65% risk of developing breast cancer 77 
and a 18-40% risk of developing ovarian cancer till 70 years age.1, 2 Higher 78 
penetrance estimates have been reported in series of high-risk families with multiple 79 
cancer cases ascertained through genetic clinics.3-6  80 
 81 
Risk reducing salpingo-oophorectomy (RRSO) has been shown to be the most 82 
effective option for preventing tubal/ ovarian cancer, with a hazard ratio (HR) of 0.21 83 
(95%CI 0.12, 0.39)7 having been reported on meta-analysis in known BRCA carriers. 84 
Oophorectomy has also been found to half the risk of subsequent breast cancer in 85 
premenopausal women who have not undergone prophylactic mastectomy.7 Screening 86 
for ovarian cancer in this population is still of unproven benefit and is currently 87 
recommended only within the context of a research study. The advantage of reduction 88 
in ovarian cancer risk with RRSO must be weighed against the as yet unproven 89 
benefit of screening in this population, anxiety associated with false positive 90 
surveillance results as well as the potential surgical risks8-10 and residual risk of 91 
primary peritoneal cancer.11 Despite the lack of evidence of benefit, many women opt 92 
for screening and RRSO uptake rates have been found to vary considerably within 93 
centres as well as between countries.12, 13 94 
 95 
In addition in premenopausal women, RRSO also leads to the onset of premature 96 
menopause and the loss of subsequent fertility. Premature menopause has been 97 
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associated with a higher risk of cardiovascular disease,14-16 potential cognitive 98 
impairment and Parkinsonism,17-19 osteoporosis, vasomotor symptoms, and 99 
detrimental impact on quality of life.20, 21 A potential mortality impact22 has also been 100 
described. Risks seem to be higher for women who undergo the procedure under the 101 
age of 45 and do not take hormone replacement therapy (HRT).21, 22 Thus, the timing 102 
of surgery is of significant importance and the choices high-risk women make may 103 
change over time. However, only three of the previous reports evaluating uptake of 104 
preventative surgery in BRCA carriers report a time to event analysis.23-25 A study of 105 
306 Dutch BRCA1/BRCA2 carriers found a 75% RRSO uptake rate over a 10 year 106 
period.24 A study from Chicago, found a 70% uptake over a 7 year period in 88 107 
BRCA1/BRCA2 carriers.25 A Manchester based study of 212 BRCA1/2 carriers 108 
reported higher uptake in BRCA1 (52%) compared to BRCA2 carriers (28%) over a 7 109 
year period.23 The median time to surgery in these studies varied from 12.5 to 34 110 
months. 111 
 112 
Here we undertake a time to event analysis to report on the factors affecting uptake of 113 
RRSO in high-risk women attending a tertiary multidisciplinary gynaecological 114 
familial cancer clinic. The uniqueness of our cohort includes the presence of a large 115 
number of women from high-risk families for whom genetic testing is unavailable in 116 
the UK due to the absence of a live affected relative. Moreover, for the first time in 117 
such an analysis we use a competing risk method which reduces potential bias related 118 
to censoring associated with Kaplan Meier26 and standard Cox27 models in earlier 119 
reported time to event analyses.  120 
 121 
 122 
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Materials and Methods 123 
The familial gynaecological cancer clinic at UCLH is a tertiary level clinic for 124 
managing women at ‘high-risk’ for familial gynaecological cancer. Women were 125 
identified from the clinic’s bespoke database as high-risk on the basis of the inclusion 126 
criteria (family history / mutation status) for the United Kingdom Familial Ovarian 127 
Cancer Screening Study (UKFOCSS) (Supplemental table-1).9, 28 BRCA gene testing 128 
within the UK National Health Service (NHS) is primarily available to cancer affected 129 
individuals from high-risk families (≥20% carrier probability) or individuals from a 130 
family with a confirmed BRCA mutation. Thus a number of high-risk women in the 131 
UK are unable to access gene testing and are of unknown mutation status (UMS). 132 
 133 
Women are managed within the context of a multi-disciplinary team, which includes 134 
gynaecological oncologists, a radiologist, a clinical geneticist, a clinical psychologist, 135 
a clinical nurse specialist, minimal access gynaecologists and a pathologist.9 All 136 
women attending the clinic undergo a pedigree-based clinical risk assessment and 137 
receive comprehensive advice on the advantages and disadvantages of RRSO and 138 
ovarian cancer screening as well as reproductive and life style issues. The primary 139 
recommendation for high-risk women is RRSO after the age of 40, if her family is 140 
completed. Premenopausal women undergoing surgery are generally advised short 141 
term HRT till the age of 50 years. Screening for ovarian cancer is available in the 142 
context of a national trial, UKFOCSS for those >35 years age.  143 
 144 
Prior to RRSO, all high-risk women undergo a pre-operative CA125 and transvaginal 145 
ultrasound scan (TVS). Surgery involves removal of both tubes and ovaries (or all 146 
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remaining adnexae in women who had undergone previous partial removal), 147 
peritoneal washings for cytological examination and endometrial sampling.  148 
 149 
Prospectively collected demographic, clinical and pathology data were stored in a 150 
bespoke database and used for the current analysis. Where necessary, hospital case 151 
notes as well as pathology records were reviewed. The database was searched for 152 
high-risk women from breast and/or ovarian cancer families who had their first clinic 153 
visit between April-2004 and November-2009. Women who had amenorrhoea for 12 154 
months (excluding those with a medical or physiological explanation such as, Mirena 155 
IUS, hormonal therapy or breast feeding) were considered to be postmenopausal.   156 
Statistical Analysis:  157 
The effect of individual variables on RRSO was initially evaluated using univariate 158 
analysis. The Mann-Whitney non-parametric test was used to compare age 159 
distributions between groups after reviewing histograms. Chi-Square with Yates’ 160 
continuity correction and Fisher’s exact test were used to calculate the difference 161 
between proportions. Two sided p values are reported for all statistical tests.  162 
 163 
Competing Risk Analysis: 164 
In a competing risks setting, the main disadvantage of standard survival analysis 165 
methods relates to censoring. Popular methods, such as the Kaplan-Meier estimator or 166 
the Cox proportional hazards model assume that censoring is non-informative and 167 
independent.26, 27 Patients who withdraw or are lost to follow-up during the study are 168 
classified as censored and are assumed to have the same risk of RRSO (event of 169 
interest) as others who are alive and have not undergone RRSO at the end of the 170 
study. However, women who undergo a competing risk event such as death from 171 
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unrelated causes during the study are also treated as censored within a Kaplan-Meier 172 
analysis. But, as they are deceased they are no longer at risk of RRSO. Some women 173 
who are undergoing screening will have to undergo surgery due to a screen detected 174 
abnormality. This would not be true ‘prophylactic surgery’. Thus there may be a 175 
number of reasons (competing risks) as a result of which women cannot subsequently 176 
opt for RRSO. Using the traditional Kaplan-Meier product-limit method in such 177 
situations gives a false/ over-inflated picture of the cumulative incidence of the event 178 
of interest (RRSO). Hence, in the presence of competing risks, instead of the 179 
traditional Kaplan-Meier method26 we have used a competing risk / actuarial 180 
cumulative incidence analysis used that considers cause-specific hazard functions (i.e 181 
for each competing risk separately).29  182 
 183 
In this analysis, we have used a competing risk method to model the cumulative 184 
incidence function (CIF) of RRSO over time. The cumulative incidence function 185 
gives the cumulative probability of occurrence of a particular event type in the 186 
presence of other (=competing) events and is a function of both the survival function 187 
and cause-specific hazard function at time t. Withdrawals due to death; bilateral 188 
salpingo-oophorectomy resulting from a screen detected abnormality; and negative 189 
genetic test for a known predisposing mutation in the family were treated as 190 
competing risks. Individuals were censored at the point of all other reasons for 191 
withdrawal or at last follow-up (study end).  192 
 193 
The impact of individual variables on the cumulative incidence function was 194 
calculated for RRSO and competing risk events. In addition to CIF plots for different 195 
factor levels, the significance was assessed univariately using Gray’s test for 196 
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subhazard distributions. This is similar to the familiar log-rank test, except that in the 197 
latter test a subject with a competing event would exit the ‘at risk’ set whereas in 198 
Gray’s test the subject remains ‘at risk’ forever.30, 31 199 
 200 
It is expected that many of the identified covariates will be correlated, and provide 201 
similar information. We chose to identify those factors that have a uniquely strong 202 
relationship with time to RRSO. A competing risks version of the Cox proportional 203 
model allows a regression of multiple variables on time to RRSO. In this model, the 204 
exponentiated coefficients are known as the subhazard ratios (SHR), and were used to 205 
assess the strength of association for a variable with the primary event’s subhazard 206 
distribution, which is directly related to the CIF. As with the standard Cox model, the 207 
assumption of proportional subhazards means the effect of the SHRs work 208 
multiplicatively on the baseline subhazard. Selection of variables was via a forward 209 
stepwise regression with inclusion set at p=0.05 and exclusion at p=0.1.This analysis 210 
was undertaken using Stata 11.0. and the ‘cmprsk’ package written for R. Two sided p 211 
values are reported for all statistical tests.  212 
 213 
Results 214 
Between April 2004 and November 2009, 1241 high-risk women from breast and/or 215 
ovarian cancer families attended clinic (initial visit) and underwent risk assessment 216 
and counselling. Of these, 108 (8.7%) were <35 years and deferred decision making. 217 
Of the remaining 1133 women by November 2009, 265 (21.4%) underwent RRSO 218 
and 868 (69.9%) opted for screening within UKFOCSS. Of the women being 219 
screened, 105 (12.1%) withdrew during the study period. Of these 43 (4.95%) 220 
underwent surgery for a screen detected abnormality, 27 (3.1%) tested negative for a 221 
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known familial BRCA mutation, 9 (1%) moved residence, 10 (1.1%) changed their 222 
mind and 16 (1.8%) gave no reason for withdrawal. Detailed characteristics of the 223 
cohort are described in Table-1.  224 
 225 
Of the 1133 women, 157 were BRCA1 carriers, 130 were BRCA2 carriers, and 3 226 
carried both a BRCA1 and BRCA2 mutation. 843 women had unknown mutation 227 
status, of whom 43% were from breast cancer only, 83% from breast and ovarian 228 
cancer and 95% from ovarian cancer only families. Women undergoing RRSO were 229 
older (median age 49, IQR 12.2years) than those opting for screening (median age 230 
43.4, IQR 11.9 years) (p<0.0005). The median time to RRSO was 36.53 (IQR 17.65, 231 
52.64) months. Initial univariate analysis showed that women who carried a BRCA1/2 232 
mutation, were post-menopausal, had a personal history of breast cancer, and were 233 
from breast cancer only families were more likely to opt for RRSO over screening 234 
(Table-1).  235 
 236 
On competing risk analysis the overall cumulative probability of undergoing 237 
prophylactic surgery in the entire cohort over 60 months was 0.29 (95%CI 0.26, 0.32). 238 
The cumulative probability for undergoing RRSO at 5 years was 0.55 (95%CI 239 
0.45,0.64) for BRCA1/2 carriers and 0.22 (95%CI 0.19,0.26)  for women of UMS. 240 
Gray’s test showed this difference between BRCA carriers and UMS women to be 241 
highly significant (p<0.0001) for RRSO but not for competing risk events (p=0.111) 242 
(Table-2, Fig-1). Similarly the CIF for RRSO was significantly different between pre- 243 
and post-menopausal groups, women with and without a personal history of breast 244 
cancer, those with and without a history of ovarian cancer <50 years in the family, 245 
nulliparous women and those with parity≥1, as well as between women from breast 246 
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cancer only families and those from breast and ovarian/ ovarian only families (Table-247 
3).  Menopausal status (p=0.251), a personal history of breast cancer (p=0.327), 248 
history of early onset ovarian cancer in the family (p=0.698), parity (p=0.396) and a 249 
family history of breast cancer (p=0.191) did not have any significant affect on 250 
competing risk events (Fig 2a, 2b, 2c, 2d and 2e respectively). We also found the CIF 251 
to be significantly different for RRSO between age groups of 30-40 years, 40-50 252 
years, 50-60 years, 60-70 years and 70-80 years (p<0.0001, Fig 2f), but not for the 253 
competing risk events (p=0.553). 254 
 255 
A competing risk regression assuming proportional subhazards was undertaken to 256 
identify the key covariates from Table-1 which remained significant for RRSO 257 
(Table-4). In the final model, the sub hazard ratios (SHR) were 2.31 (95%CI 1.7, 258 
3.14) for BRCA1/2 carriers, 2.16 (95%CI 1.62, 2.87) for postmenopausal women, and 259 
1.5 (95%CI 1.09, 2.06) for those with a personal history of breast cancer. The SHR of 260 
1.43 (95%CI 0.99, 2.06) for parity≥1 neared statistical significance (p=0.056) and 261 
remained part of the final equation (Table-4). All SHRs were greater than one, 262 
indicating that an increase (or presence) in this factor increased the subhazard and 263 
hence the CIF for RRSO.  264 
  265 
Discussion 266 
Our study highlights that counselling and decision making for women at high risk of 267 
familial ovarian cancer is a complex process and women continue to opt for surgery 268 
many years after their initial risk assessment. It re-emphasises the previously reported 269 
dynamic nature of decision making which changes over time.23-25 BRCA carriers, 270 
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postmenopausal women and those who have had breast cancer are significantly more 271 
likely to opt for risk reducing surgery. 272 
 273 
The cumulative probability of undergoing prophylactic surgery in our cohort was 0.29 274 
(95%CI 0.26, 0.32). This is less than most reports in the literature, where varying 275 
RRSO uptake rates ranging from 15% to 78% have been reported, but the majority are 276 
over 48%.12 However, the bulk of all these reports include BRCA carriers in the main 277 
and are limited by not accounting for time in the analysis. The RRSO rates reported in 278 
previous time to event analysis vary from 45% to 75%.23-25 A significant factor 279 
accounting for our lower uptake is the larger proportion of women of unknown 280 
mutation status (CIF of 22.2% at 60 months) in our cohort. This low level of uptake in 281 
untested women has been reported in one previous small series,32 and is in keeping 282 
with previous reports of a positive BRCA genetic test result being a predictor of 283 
RRSO uptake.32, 33 The CIF for RRSO of 54.5% at 60 months found in BRCA1/2 284 
carriers in our cohort is consistent with one previous time to event analysis23 but 285 
lower than other reports in the literature.24, 25, 34 In addition to restricted access to 286 
genetic testing in the UK these differences may also be due to heterogeneity of 287 
populations, individual preferences or other psychosocial factors. The ability to opt 288 
for a national ovarian cancer screening study at our centre may also have contributed 289 
to these results.  290 
 291 
The strengths of our study include its large size, a mixed cohort of women with 292 
known BRCA mutations and unknown mutation status, longitudinal nature of follow-293 
up, prospectively collected data and use of the competing risk method for analysis. To 294 
the best of our knowledge ours is the largest series with high-risk women who were 295 
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unable to, or chose not to undergo genetic testing for BRCA1/2 mutations. Our study 296 
is different from previous time to event analysis24, 25 as it helps to highlight the 297 
differences in genetic testing practices in the UK and elsewhere in the world. Our data 298 
that BRCA carriers are 2.3 times more likely to opt for preventative surgery suggests 299 
that uptake of prophylactic oophorectomy may vary with level of proven ovarian 300 
cancer risk. Such a finding of risk-linked uptake of preventative surgery has 301 
previously been reported for prophylactic mastectomy.23 One time to event analysis23 302 
reported an increased RRSO rate in BRCA1 carriers who are known to have a higher 303 
risk compared to BRCA2 carriers.23, 35 However, consistent with the Dutch study,24 304 
and most other analyses we did not find a significant difference in RRSO rates 305 
between BRCA1 and BRCA2 carriers (p=0.54). Increasing access to genetic testing in 306 
the UK with resultant confirmation of risk may lead to higher RRSO uptake rates with 307 
the potential to reduce ovarian/tubal cancer incidence in high-risk women.  308 
 309 
Our study is one of the few to explore time as a factor in the uptake of preventative 310 
surgery. Another advantage of our study is the use of competing risk methodology. 60 311 
(57%) of the 105 withdrawals in our study were due to a competing risk event. These 312 
women could not have subsequently undergone RRSO. Within a routine Kaplan-313 
Meier analysis these cases would be considered at similar risk of subsequent events as 314 
other subjects with continued follow-up. In fact most other studies do not report 315 
details of reasons for salpingo-oophorectomy. Competing risks have not been reported 316 
in three previous time-to-event analyses of preventative surgery for BRCA carriers.23-317 
25 It is possible this bias may have contributed to the higher rates of prophylactic 318 
salpingo-oophorectomy reported in those series.  319 
 320 
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We found that women continue to opt for RRSO many months / years after their 321 
initial decision. A significant proportion of BRCA carriers underwent surgery >12-24 322 
months after their initial counselling appointment following results of genetic testing 323 
(Table-2). This is in contrast with most previous reports suggesting that BRCA 324 
carriers undergo surgery within a year after learning their genetic test result36-38 but 325 
consistent with three recent time to event analysis24, 25 indicating that BRCA carriers 326 
continue to opt for surgery many years later. Our data indicate that this finding also 327 
holds true for women with unknown mutation status, with only half of those women 328 
opting for surgery doing so within 12 months of their initial consultation (Table-2). 329 
The overall median time to RRSO in our study was greater than the Chicago study25 330 
but similar to a Dutch study.24 331 
 332 
Consistent with findings of others,25, 32, 36, 39 including two previous time to event 333 
analysis,24, 25 we found that increasing age (Fig 2f) and having children (Fig 2d) were 334 
factors associated with RRSO uptake. The median age of women opting for RRSO in 335 
our study is slightly older than most other reports in the literature, including the Dutch 336 
and Chicago study.24, 25 The Manchester study23 like ours found a significant 337 
difference in RRSO uptake across age groups. However, they reported higher uptake 338 
rates with time in younger women, while we found an increasing RRSO uptake with 339 
increasing age (Fig 2f). Postmenopausal women in our study were 2.16 times more 340 
likely to opt for RRSO. Although menopause was not reported as an independent risk 341 
factor in previous time to event analyses it has been found to be of importance in 342 
other studies.34 Pre-menopausal women are more likely to be younger, nulliparous, 343 
have concerns regarding detrimental effects of the menopause and hence, delay 344 
surgery.23, 25 345 
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Our finding of a personal history of breast cancer being associated with increased 346 
RRSO uptake was not reported in earlier time to event analyses23-25 but has been 347 
described by other series.13, 21, 38, 40, 41 However, in contrast with some other reports we 348 
did not find that having a first degree relative with ovarian cancer35, 42 or a family 349 
history of early onset breast cancer were significant predictors of RRSO. The finding 350 
that a history of early onset ovarian cancer (<50 years) in the family was inversely 351 
associated with uptake of preventive surgery on univariate analysis is likely to be a 352 
confounding effect or chance finding as it was not maintained following multivariable 353 
competing risk regression analysis. Although the Chicago study reported a family 354 
history of ovarian cancer to be a significantly associated with RRSO uptake, this was 355 
not observed in our study or the other time to event analyses.23, 24 We did not find 356 
Jewish ethnicity to be a factor affecting uptake of risk reducing surgery in our cohort. 357 
A lower surgical uptake has been reported in some minority populations such as 358 
African-American populations.25  359 
 360 
Multivariable regression analysis (Table-4) indicated that the main factors affecting 361 
decision making were having a BRCA gene mutation, being postmenopausal, a 362 
personal history of breast cancer and having children. The fact that these factors did 363 
not have any significant effect on competing risk events (Fig 1, 2a, 2b, 2c, 2d) is 364 
reassuring as it suggests that competing risk events in the cohort occurred 365 
independently of co-variates of significance. Although Gray’s test showed a 366 
significant difference in RRSO uptake across age groups, age was not part of the final 367 
model, as the effect of this variable was probably accounted for by menopausal status 368 
in the equation. It is interesting to note that the SHR for postmenopausal status was 369 
similar to that for carrying a BRCA carrier status indicating that the magnitude/ 370 
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contribution of these factors towards decision making was similar in high-risk 371 
women. Limitations of our analysis are that we lacked data on factors such as 372 
psychosocial factors, perceived risk, cancer worry and fear of surgery, which have 373 
been shown to affect uptake of preventative surgery.34, 43, 44 In addition it was not 374 
possible to assess whether decision making varied depending on the individual 375 
clinician (from the familial clinic team) seen at each consultation.  376 
 377 
The study has important implications for counselling/ management  and for planning/ 378 
commissioning of services of women at high-risk of familial ovarian/tubal cancer, 379 
particularly in the UK and other countries with restricted access to genetic testing.  It 380 
adds to  the knowledge base related to factors influencing RRSO in high-risk women 381 
and the amount of time that this decision-making process can take.  It also highlights 382 
the large number of high-risk families with no living cancer affected relatives who 383 
could benefit from expanded genetic testing to further clarify their cancer risks as well 384 
as access to risk management options. 385 
 386 
Conclusion 387 
A large number of high-risk women find bilateral salpingo-oophorectomy to be an 388 
acceptable option for reducing their risk of ovarian and tubal cancer. Decision making 389 
is a complex and dynamic process which changes over time. Women continue to opt 390 
for surgery many years after their initial counselling and risk assessment. Clinicians 391 
should pursue follow-up opportunities with their high-risk patients as many will delay 392 
decision making. A number of different factors affect uptake of risk reducing surgery 393 
in these women. RRSO uptake is risk dependent with lower uptake rates in high risk 394 
women who are unaware of their mutation status. A number of women delay surgery 395 
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until they have completed their families or reached the menopause. Known BRCA 396 
carriers and women who have had breast cancer are more likely to opt for 397 
preventative surgery. Recognition and appreciation of these matters can assist in 398 
planning and commissioning of services for high-risk women. Relaxation of BRCA 399 
testing criteria in the UK may lead to greater access to genetic testing, detection of 400 
more carriers and increased RRSO uptake.  Risk management options need to be 401 
individualised for each woman and it is important for clinicians to be aware of these 402 
issues when counselling women at increased risk.  403 
 404 
405 
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Table-1: Baseline characteristics of the cohort  
 
 RRSO (n= 265) Screening (n= 868) p value 
Median age (IQR) 49 (12.2) 43.4 (11.9) <0.0005 ¥ 
BRCA 1,2 Carriers 111 (41.9%) 179 (20.6%) <0.0005 # 
BRCA1 63 (23.8%) 97 (11.2 %) <0.0005 # 
BRCA2 48 (16.7%) 85 (7.7%) <0.0005 # 
BRCA1+2 0 3 1 * 
UMS 154 (58.1%) 689 (79.4%) <0.0005 # 
Post-menopausal 138 (52.1%) 251`(28.9%) <0.0005 # 
Parity ≥1 189/225 (84%) 624/818 (76.3%) 0.013 # 
Jewish Ancestry 54/254 (18%) 203/847 (19.5%) 0.371 # 
FAMILY HISTORY    
HBC 76/259 (29.3%) 195/847 (23%) 0.038 # 
HBOC 150/259 (57.9%) 517/847 (61%) 0.369 # 
HOC 31/259 (12%) 133/846 (15.7%) 0.162 * 
FDR Breast cancer 138/258 (53.5%) 443/846 (52.4%) 0.752 # 
FDR Ovarian cancer 125/258 (48.4%) 455/845 (53.8%) 0.129 # 
FH of Ovarian cancer 
<50yrs 
64/257 (24.9%) 271/846 (32%) 0.029 # 
FH of Breast cancer 
<45yrs 
148/257 (57.6%) 466/845 (55.1%) 0.491 # 
Self breast cancer 97/258 (37.6%) 157/845 (18.6%) <0.0005 
# 
 
FDR- First degree relative, FH- Family History, HBC- High-risk breast cancer only 
family, HBOC- high-risk breast and ovarian cancer family, HOC- High-risk ovarian 
cancer only family, IQR- Inter-quartile range, RRSO- Risk reducing salpingo-
oophorectomy, UMS- Unknown mutation status,  yrs- years 
# Chi Square, * Fisher’s exact test, ¥ Mann Whitney Test 
Using a Bonferroni correction for multiple testing the above p values should be 
compared with a critical value of α= 0.003 
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Table-2: Cumulative RRSO Probability (CIF) by BRCA1/2 status over time  
 
Months 12 24 36 48 60 Gray’s Test 
BRCA1/2 CIF 0.299 0.381 0.429 0.482 0.545 RRSO incidence 
BRCA1/2 vs. UMS:  
p<0.0001 95% CI 
(0.243, 
0.355) 
(0.319, 
0.443) 
(0.362, 
0.496) 
(0.406, 
0.557) 
(0.449, 
0.641) 
UMS CIF 0.114 0.173 0.192 0.204 0.222 Competing Risk 
incidence BRCA1/2 
vs. UMS: p= 0.111 95% CI 
(0.092, 
0.136) 
(0.146, 
0.200) 
(0.163, 
0.221) 
(0.174, 
0.234) 
(0.189, 
0.256) 
 
 
CIF- Cumulative Incidence Function, CI- confidence interval, RRSO- Risk reducing 
salpingo-oophorectomy , UMS- Unknown mutation status,  
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Table-3: Cumulative RRSO Probability (CIF) at 5 years 
 
Variable 
Cumulative 
RRSO 
Probability 
95% CI Gray’s Test Figure 
Premenopausal 0.23 0.19, 0.27 
p<0.0001 2a 
Postmenopausal 0.42 0.36, 0.47 
Personal h/o breast 
cancer 0.47 0.39, 0.55 p<0.0001 2b No personal h/o breast 
cancer 0.24 0.21, 0.28 
FH of early onset ovarian 
cancer 0.23 0.18, 0.28 p=0.006 2c No FH of early onset 
ovarian cancer 0.32 0.28, 0.37 
Nulliparous 0.20 0.14, 0.27 
p=0.009 2d 
Parity≥1 0.29 0.25, 0.33 
FH: breast cancer only 
family 0.35 0.43, 0.28 
p=0.006 2e FH: breast and 
ovarian/ovarian cancer 
only families 
0.27 0.24, 0.31 
 
 
CIF- Cumulative Incidence Function, CI- confidence interval, FH- family history, h/o- 
history of, RRSO- Risk reducing salpingo-oophorectomy  
 
 
 
 
 
 
 4
Table-4: Competing Risk Multivariable Regression Analysis for RRSO 
 
Co-variate SHR Std. Err. z P>z [95% CI] 
Parity ≥1 1.428 0.266221 1.91 0.056 0.990813 2.05776 
Postmenopausal 2.158 0.314172 5.28 <0.0001 1.621955 2.870272 
BRCA1/2 2.314 0.361977 5.36 <0.0001 1.70296 3.14422 
Self Breast 
Cancer 1.501 0.243502 2.5 0.012 1.0921 2.062774 
 
CI- confidence interval, SHR- Sub-Hazard Ratio, Std. Err- standard error, Self Breast 
Cancer- personal history of breast cancer. 
 
 
 


